|
1 |
Effektivität, Immunogenität und Sicherheit eines Re-switches von Biosimilar SB2 auf Originator Infliximab bei Patienten mit chronisch entzündlichen Darmerkrankungen: 12-Monats-Daten einer prospektiven Beobachtungsstudie Donhauser, Moritz. - Erlangen : Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 2025
|
|
|
2 |
A Cost-Effectiveness Analysis of Gonadotropins Used for Ovarian Stimulation during Assisted Reproductive Technology Based on Data from the French Nationwide Claims Database (SNDS) Enthalten in Gynecologic and obstetric investigation Bd. 90, 2025, Nr. 3: 211-225. 15 S.
|
|
|
3 |
Altersbedingte Makuladegeneration – Teil 2: therapeutische Optionen bei der AMD Enthalten in Augenheilkunde up2date Bd. 15, 2025, Nr. 02: 101-115
|
|
|
4 |
Altersbedingte Makuladegeneration – Teil 2: therapeutische Optionen bei der AMD Enthalten in Klinische Monatsblätter für Augenheilkunde 19.05.2025
|
|
|
5 |
Effects of Generic Entry on Market Shares and Prices of Originator Drugs: Evidence from Chinese Pharmaceutical Market Enthalten in PharmacoEconomics - open 19.3.2025: 1-10
|
|
|
6 |
Innovation und KI Enthalten in Ideen- und Innovationsmanagement 2025, Nr. 02: 44-50
|
|
|
7 |
Acceptance and Commitment Therapy for Insomnia Cham : Springer Nature Switzerland, Imprint: Springer, 2024, 1st ed. 2024
|
|
|
8 |
Attachment Centred Therapy Shults, Charley. - Cham : Springer Nature Switzerland, Imprint: Palgrave Macmillan, 2024, 1st ed. 2024
|
|
|
9 |
Reverse switching from the biosimilar SB2 to the originator infliximab in previously switched patients with inflammatory bowel diseases: results of a prospective long-term cohort study Fischer, Sarah. - Erlangen : Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 2024
|
|
|
10 |
Inpatient Infliximab Biosimilar Cost-Savings: Cost Analysis of Inpatient Treatment with Originator Infliximab (Remicade ™) versus Biosimilar Infliximab (Renflexis ™) for Acute Severe Ulcerative Colitis Enthalten in Digestive diseases Bd. 42, 2024, Nr. 5: 496-502. 6 S.
|
|